跳转至内容
Merck
CN
  • Implementation of the thin layer agar method for diagnosis of smear-negative pulmonary tuberculosis in a setting with a high prevalence of human immunodeficiency virus infection in Homa Bay, Kenya.

Implementation of the thin layer agar method for diagnosis of smear-negative pulmonary tuberculosis in a setting with a high prevalence of human immunodeficiency virus infection in Homa Bay, Kenya.

Journal of clinical microbiology (2009-06-06)
Anandi Martin, Peter Munga Waweru, Fred Babu Okatch, Naureen Amondi Ouma, Laurence Bonte, Francis Varaine, Françoise Portaels
摘要

The objective of this study was to evaluate the performance of a low-cost method, the thin layer agar (TLA) method, for the diagnosis of smear-negative patients. This prospective study was performed in Homa Bay District Hospital in Kenya. Out of 1,584 smear-negative sputum samples, 212 (13.5%) were positive by culture in Löwenstein-Jensen medium (LJ) and 220 (14%) were positive by the TLA method. The sensitivities of LJ and TLA were 71% and 74%, respectively. TLA could become an affordable method for the diagnosis of smear-negative tuberculosis in resource-limited settings, with results available within 2 weeks.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲氧苄啶, ≥98.5%
Sigma-Aldrich
甲氧苄啶, ≥99.0% (HPLC)
Supelco
甲氧苄啶, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
甲氧苄啶, VETRANAL®, analytical standard